Literature DB >> 16121341

Clinicopathological features, surgical management, and disease outcome of perforated gastric cancer.

Shyh-Chuan Jwo1, Rong-Nan Chien, Tzu-Chien Chao, Huang-Yang Chen, Chin-Yew Lin.   

Abstract

BACKGROUND AND OBJECTIVES: Perforated gastric cancer is rare and generally not diagnosed preoperatively or intraoperatively, if a frozen section is unavailable. Therefore, the elucidation of its clinicopathological features and disease outcomes will help surgeons manage perforated gastric cancer. PATIENTS AND METHODS: The clinicopathological features, surgical management, and disease outcomes of 13 patients with perforated gastric cancer from March 1989 to May 2003 were retrospectively analyzed. Disease outcomes were analyzed in-depth based on tumor stage, depth of tumor invasion, operative curability, and three treatment groups.
RESULTS: All 13 patients (median age of 72 years) received emergent laparotomy. Malignant gastric perforation was diagnosed intraoperatively in eight (61.5%) patients. Four patients whose frozen sections exhibited perforated gastric cancer underwent radical surgery with curative intent and were assigned to Group 1. Another four patients with overt distal metastases underwent palliative surgery and were assigned to Group 2. The remaining five patients were misdiagnosed as having benign gastric perforation and underwent local surgery; these patients were assigned to Group 3. All patients received follow-up for a median of 26 months. The survival rates for Stage I disease (P = 0.0342), T1/T2 tumors (P = 0.0342), and curative resection (P = 0.0012) significantly exceeded those of Stage III/IV, T3/T4 tumors, and non-curative resection. Additionally, the survival rates of Group 1 (P = 0.0067) and Group 3 (P = 0.0067) significantly exceeded those of Group 2. Stepwise logistic regression analysis revealed no significant predictor of prognosis.
CONCLUSIONS: In resectable cases, one-stage radical gastrectomy with possible extensive lymphadenectomy should be encouraged if conditions allow. In cases of misdiagnosis, non-radical local surgery with curative resection is sufficient to treat early-stage cancer. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16121341     DOI: 10.1002/jso.20307

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

1.  The best surgical approach for perforated gastric cancer: one-stage vs. two-stage gastrectomy.

Authors:  Tatsuo Hata; Naoaki Sakata; Katsuyoshi Kudoh; Chikashi Shibata; Michiaki Unno
Journal:  Gastric Cancer       Date:  2013-10-12       Impact factor: 7.370

2.  Perforations of the esophagus and stomach: what should I do?

Authors:  Francesca Dimou; Vic Velanovich
Journal:  J Gastrointest Surg       Date:  2014-12-02       Impact factor: 3.452

Review 3.  Surgical management of gastric perforation in the setting of gastric cancer.

Authors:  Alyson L Mahar; Savtaj S Brar; Natalie G Coburn; Calvin Law; Lucy K Helyer
Journal:  Gastric Cancer       Date:  2011-10-08       Impact factor: 7.370

4.  Perforated tumours in the gastrointestinal tract: CT findings and clinical implications.

Authors:  S W Kim; H C Kim; D M Yang
Journal:  Br J Radiol       Date:  2012-04-11       Impact factor: 3.039

5.  Perforation of gastric cancer - What should the surgeon do?

Authors:  Nebojsa Ignjatovic; Dragan Stojanov; Miodrag Djordjevic; Jelena Ignjatovic; Daniela Benedeto Stojanov; Bobana Milojkovic
Journal:  Bosn J Basic Med Sci       Date:  2016-04-13       Impact factor: 3.363

6.  Outcome after emergency surgery in patients with a free perforation caused by gastric cancer.

Authors:  Hironori Tsujimoto; Shuichi Hiraki; Naoko Sakamoto; Yoshihisa Yaguchi; Takuya Horio; Isao Kumano; Takayoshi Akase; Hidekazu Sugasawa; Satoshi Aiko; Satoshi Ono; Takashi Ichikura; Hase Kazuo
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

7.  2013 WSES guidelines for management of intra-abdominal infections.

Authors:  Massimo Sartelli; Pierluigi Viale; Fausto Catena; Luca Ansaloni; Ernest Moore; Mark Malangoni; Frederick A Moore; George Velmahos; Raul Coimbra; Rao Ivatury; Andrew Peitzman; Kaoru Koike; Ari Leppaniemi; Walter Biffl; Clay Cothren Burlew; Zsolt J Balogh; Ken Boffard; Cino Bendinelli; Sanjay Gupta; Yoram Kluger; Ferdinando Agresta; Salomone Di Saverio; Imtiaz Wani; Alex Escalona; Carlos Ordonez; Gustavo P Fraga; Gerson Alves Pereira Junior; Miklosh Bala; Yunfeng Cui; Sanjay Marwah; Boris Sakakushev; Victor Kong; Noel Naidoo; Adamu Ahmed; Ashraf Abbas; Gianluca Guercioni; Nereo Vettoretto; Rafael Díaz-Nieto; Ihor Gerych; Cristian Tranà; Mario Paulo Faro; Kuo-Ching Yuan; Kenneth Yuh Yen Kok; Alain Chichom Mefire; Jae Gil Lee; Suk-Kyung Hong; Wagih Ghnnam; Boonying Siribumrungwong; Norio Sato; Kiyoshi Murata; Takayuki Irahara; Federico Coccolini; Helmut A Segovia Lohse; Alfredo Verni; Tomohisa Shoko
Journal:  World J Emerg Surg       Date:  2013-01-08       Impact factor: 5.469

8.  WSES consensus conference: Guidelines for first-line management of intra-abdominal infections.

Authors:  Massimo Sartelli; Pierluigi Viale; Kaoru Koike; Federico Pea; Fabio Tumietto; Harry van Goor; Gianluca Guercioni; Angelo Nespoli; Cristian Tranà; Fausto Catena; Luca Ansaloni; Ari Leppaniemi; Walter Biffl; Frederick A Moore; Renato Poggetti; Antonio Daniele Pinna; Ernest E Moore
Journal:  World J Emerg Surg       Date:  2011-01-13       Impact factor: 5.469

9.  An analysis of 13 patients with perforated gastric carcinoma: A surgeon's nightmare?

Authors:  Cetin Kotan; Aziz Sumer; Murat Baser; Remzi Kızıltan; M Ali Carparlar
Journal:  World J Emerg Surg       Date:  2008-05-10       Impact factor: 5.469

10.  Perforated Carcinoma in the Gastric Remnant: A Case of Conservative Treatment Prior to Successful Curative R0 Resection.

Authors:  Ken Yuu; Hiroshi Kawashima; Sho Toyoda; Satoshi Okumura; Kansuke Yamamoto; Naoto Mizumura; Aya Ito; Hiromitsu Maehira; Atsuo Imagawa; Masao Ogawa; Masayasu Kawasaki; Masao Kameyama
Journal:  Case Rep Surg       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.